pcn poster

Posters

Impact of Adjunctive Cariprazine on Quality of Life in Major Depressive Disorder: A Post Hoc Analysis

Patients with major depressive disorder often have reduced quality of life. A previous phase 3 trial showed cariprazine adjunctive to antidepressant therapy reduces depressive symptoms in...

Nadia Nabulsi , MPH, PhD;

10/26/2023

Impact of AXS-05 (Dextromethorphan-Bupropion) on Patient-Reported Insomnia Symptoms: Results from the GEMINI Trial

In GEMINI, AXS-05, an oral NMDA receptor antagonist approved for MDD, showed significantly higher response rates (defined as 50% reduction in QIDS insomnia score) starting at Week 3 throu...

William Olsufka , PharmD;

10/26/2023

Familiarity With Psychiatric Pharmacogenomic Testing in Physicians and Advanced Practice Providers: Educational Opportunities

This survey of 305 U.S. providers identified current pharmacogenomic testing trends and learning opportunities among MDs/DOs and advanced practice providers. Most respondents were unfamil...

Priya Maheshwari , RPh;

10/26/2023

From Relief to Aggravation: The Intriguing Tinnitus-Opioid Withdrawal Paradox

This case report documents a patient who experienced persistent tinnitus for years after stopping heroin abuse. Tinnitus was temporarily relieved by heroin or morphine administration, wit...

Nikita Mehdiratta ;

10/26/2023

Growth Trajectories of Youth with Attention-Deficit/Hyperactivity Disorder Treated with Delayed-Release/Extended-Release Methylphenidate: A Pilot Database Analysis of Real-World Data

DR/ER-MPH is an evening-dosed delayed-release and extended-release methylphenidate that is released in the colon and provides a dose-dependent duration of effect for individuals aged ≥6y ...

Karl Weddige , PhD;

10/26/2023

Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to Selective Serotonin Reuptake Inhibitors: The VIVRE Study

This study assessed the efficacy of vortioxetine versus desvenlafaxine in patients with MDD experiencing partial response to treatment with an SSRI. Vortioxetine was noninferior to desven...

Michael Adair , MBChB;

10/26/2023

Healthcare Resource Use and Cost Associated with Negative Symptoms of Schizophrenia

Information is sparse on the burden of healthcare resource utilization (HCRU) and costs among patients with negative symptoms of schizophrenia (NSS). Using a retrospective longitudinal ob...

Monika Semwal , PhD;

10/26/2023

Estimation of Healthcare Cost Savings with Zuranolone in Major Depressive Disorder using Health-related Quality of Life to Predict Healthcare Costs

The Medical Expenditure Panel Survey was used to identify adults with major depressive disorder, to predict the association between health-related quality of life scores and annual health...

Ellison Suthoff , MBA, BS ;

10/26/2023

Evaluating the opioid epidemic in a large county jail: Who is most at risk?

This poster aims to explore the comorbidity of mental health conditions (MDD, BPD, GAD, and Schizophrenia) with opioid use disorder in people incarcerated at a large urban jail.

Conchita Martin de Bustamante ;

10/26/2023

Evaluation of Mania and Hypomania in Late-Phase Clinical Trials of Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

This analysis evaluated mania and hypomania across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week, placebo-...

Tobie Escher , PhD;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products